THTakahisa Hishiya

Takahisa Hishiya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takahisa Hishiya has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CD69 regulates the tissue dynamics of epigenetically imprinted memory CD4 + T cells

    by Rui Hirasawa, Chiaki Iwamura, Masahiro Kiuchi, Takahisa Hishiya, Atsushi Sasaki, Kohei Kakinuma, Kanae Ohishi, Akane Kurosugi, Masahiro Nemoto, Kota Kokubo, et al.

    Tissue-resident memory T cells (T RM cells) reside in nonlymphoid tissues and provide the first line of defense against pathogens. A subset of T RM cells can egress from nonlymphoid tissues into the circulation. However, the functional consequences and the extent of epigenetic imprinting in recirculating T RM cells remain unknown. We herein demonstrate that in CD4 + T RM cells, the CD69-S1PR1 axis controls tissue residency and that interrupting this axis results in ablation of lung CD4 + T RM cells. A subpopulation of CD69 + CD4 + T RM cells reentered circulation via lymphatic vessels, where they epigenetically maintained the characteristics of T RM cells in both mice and humans. Circulating Ex-lung-T RM cells in mice caused enhanced skin inflammation compared to circulating memory cells. Furthermore, we identified GPR183 and CD161 as potential markers of Ex-T RM in human peripheral blood mononuclear cells. In chronic inflammatory diseases, the transposition of allergic inflammation to multiple tissues may therefore occur via recirculation of tissue-imprinted memory CD4 + T cells.


  • Open Access

    Single-cell RNA sequencing identifies M2-like macrophage polarization associated with mesenchymal stem cell treatment in a murine sepsis model

    by Takehiko Oami, Takahisa Hishiya, Seiji Miyauchi, Chiaki Iwamura, Kiyoshi Hirahara, Taka-Aki Nakada

    Mesenchymal stem cells (MSCs) have demonstrated therapeutic potential in preclinical models of sepsis, primarily through their immunomodulatory functions. However, the specific mechanistic roles of MSCs in the pathophysiology of sepsis, particularly their interactions with immune cells, are not yet fully understood. In this study, we utilized a murine sepsis model induced by cecal ligation and puncture to assess the effects of adipose-derived MSCs on survival rates, systemic cytokine profiles, and immune cell dynamics. MSCs were administered via tail vein injection immediately after surgery. To investigate cell-specific transcriptional changes and associated pathway enrichment following MSC administration, we performed single-cell RNA sequencing (scRNA-seq) on CD45-positive immune cells isolated six hours postoperatively. Our results indicated that MSC administration significantly improved the survival of septic mice compared to controls. The scRNA-seq analysis revealed dynamic changes in immune cell populations, including increased proportions of both M1 and M2 macrophages. Transcriptomic analysis demonstrated that MSC treatment downregulated inflammatory genes such as Cd14, Cxcl2, Hmgb2, and Pde4b in M0 and M1 macrophages while upregulating regulatory and metabolic genes, including Hmox1, Maf, and Jun. In M2 macrophages, MSCs enhanced the expression of immunomodulatory genes such as Hmox1 and Ccr1, indicating a potential promotion of inflammation resolution. Pseudotime trajectory analysis suggested a transition towards M2-like transcriptional states. Overall, MSC treatment resulted in improved survival in sepsis, characterized by immune modulation, reduced inflammatory signatures, and increased M2-like macrophage profiles. These findings offer mechanistic insights into the therapeutic potential of MSCs and underscore the need for further research to optimize their clinical applications in sepsis.


  • Open Access

    Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab–Denosumab Therapy for Severe Osteoporosis

    by Akira Kuwabara, Kazuhide Inage, Masaomi Yamashita, Sumihisa Orita, Yawara Eguchi, Yasuhiro Shiga, Masahiro Inoue, Miyako Suzuki-Narita, Takahisa Hishiya, Kohei Okuyama, et al.

    Kuwabara A, et al. Yonsei Med J. 2026 Sep;67(9):680-685. https://doi.org/10.3349/ymj.2025.0262

  • Hepatic leukemia factor directs tissue residency of proinflammatory memory CD4 + T cells

    by Masahiro Kiuchi, Masahiro Nemoto, Hiroyuki Yagyu, Ami Aoki, Chiaki Iwamura, Hikaru Sugimoto, Yuki Masuo, Hajime Morita, Shuhe Ma, Yukiko Okuno, et al.

    CD4 + tissue-resident memory T (T RM ) cells contribute to host defense and to the pathogenesis of chronic inflammatory diseases, but the molecules that direct their differentiation are unknown. We found that the transcription factor hepatic leukemia factor (HLF) could direct the tissue residency program and function of CD4 + T RM cells. HLF simultaneously up-regulated tissue retention receptors, down-regulated tissue egress receptors, and promoted proinflammatory CD4 + T RM cells by inducing Bhlhe40 , and all of these processes were associated with changes in chromatin accessibility. Genetic deletion of Hlf inhibited CD4 + T RM cell generation and ameliorated airway tissue inflammation in vivo. HLF + CD4 + T RM cells isolated from inflamed airway tissue in humans had a tissue residency signature and expressed inflammatory cytokines. We conclude that HLF may act as a central regulator of proinflammatory CD4 + T RM cell development and function.


  • Lipolysis-microlipophagy cascade regulated by adipose triglyceride lipase drives pathogenic adaptive type 2 immunity

    by Hiroyuki Yagyu, Masahiro Kiuchi, Atsushi Sasaki, Eisuke Itakura, Kota Kokubo, Chiaki Iwamura, Atsushi Onodera, Ami Aoki, Takahisa Hishiya, Kaori Tsuji, et al.

    A unique subpopulation of memory T helper 2 (T H 2) cells expressing the interleukin-33 (IL-33) receptor ST2 drives allergic disease pathogenesis. However, the immunometabolic mechanisms that induce ST2 hi memory T H 2 cells remain unclear. We show using a mouse model of chronic allergic airway inflammation that long-chain unsaturated fatty acids (LC-UFAs) accumulate in the inflammatory milieu during chronic airway inflammation. Activated T H 2 cells take up LC-UFAs, transiently store them in lipid droplets (LDs), and catabolize LDs through lipolysis and microlipophagy. LD catabolism regulated by adipose triglyceride lipase (ATGL) activates peroxisome proliferator–activated receptor γ (PPARγ). PPARγ then binds the Il1rl1 locus encoding ST2 and induces ST2 hi effector and memory T H 2 cells. In eosinophilic chronic rhinosinusitis, CD45RO + CD4 T cells in nasal polyps exhibit microlipophagy and an accessible IL1RL1 enhancer, indicating that these mechanisms are conserved in humans. Thus, the storage and catabolism of inflammatory milieu–derived LC-UFAs direct pathogenic adaptive type 2 immunity, offering potential therapeutic strategies for persistent allergic inflammation.


  • Open Access

    Predictive Factors for Increased Bone Density Following Romosozumab Administration Based on Pre-Administration Blood Test Results

    by Akira Kuwabara, Kazuhide Inage, Masaomi Yamashita, Sumihisa Orita, Yawara Eguchi, Yasuhiro Shiga, Masahiro Inoue, Miyako Suzuki-Narita, Takahisa Hishiya, Takahito Arai, et al.

    Kuwabara A, et al. Yonsei Med J. 2024 Dec;66:e11. https://doi.org/10.3349/ymj.2023.0535


  • Bone union‐promoting effect of romosozumab in a rat posterolateral lumbar fusion model

    by Geundong Kim, Kazuhide Inage, Yasuhiro Shiga, Tomohito Mukaihata, Ikuko Tajiri, Yawara Eguchi, Miyako Suzuki‐Narita, Hiromitsu Takaoka, Takashi Hozumi, Norichika Mizuki, et al.

    This study investigated the effect of romosozumab on bone union in a rat posterolateral lumbar fixation model. Posterolateral lumbar fixation was performed on 8‐week‐old male Sprague Dawley rats (n = 20). For bone grafting, autogenous bone (40 mg) was harvested from the spinous processes of the 10th thoracic vertebra until the 2nd lumbar vertebra and implanted between the intervertebral joints and transverse processes of the 4th and 5th lumbar vertebrae on both sides. Rats were matched by body weight and equally divided into two groups: R group (Evenity®, 25 mg/kg) and control (C) group (saline). Subcutaneous injections were administered twice a week until 8 weeks after surgery. Computed tomography was performed at surgery and week 8 after surgery. The area and percentage of bone trabeculae in the total area of bone fusion were calculated. Statistical analysis was performed using an unpaired t test (p < 0.05). We found that the R group rats had significantly higher mean bone union rate and volume than did the C group rats at all time courses starting week 4 after surgery. The R group had significantly higher increase rates than did the C group at weeks 4 and 6 after surgery. The percentage of bone trabeculae area in the R group was approximately 1.7 times larger than that in the C group. Thus, we demonstrated that romosozumab administration has stimulatory effects on bony outgrowth at bone graft sites. We attribute this to the modeling effect of romosozumab.


  • Open Access

    Time-Course Changes in Bone Metabolism Markers and Density in Patients with Osteoporosis Treated with Romosozumab: A Multicenter Retrospective Study

    by Kazuhide Inage, Sumihisa Orita, Yawara Eguchi, Yasuhiro Shiga, Masao Koda, Yasuchika Aoki, Toshiaki Kotani, Tsutomu Akazawa, Takeo Furuya, Junichi Nakamura, et al.

    Inage K, et al. Yonsei Med J. 2021 Sep;62(9):829-835. https://doi.org/10.3349/ymj.2021.62.9.829